We have to use facilities from abroad, like gene sequencing and other things like computerized modelling of the molecule. So this is our problem, we don't have adequate supporting equipment," Chaicumpa said. "We can produce in the lab in the small scale, very small scale, [but] to go to the industrial scale, the pilot plant we have to modify the antibody molecule in such a way it can produce well in the cell culture of the factory scale